Clearmind Medicine To Present Groundbreaking Research At Psychedelic Medicine – Israel 2024 Conference

By Author: Orson Amiri
Total Articles: 334
Comment this article

Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company, will participate in the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28th to 30th. This event gathers global experts in psychedelic medicine. Clearmind's CEO, Adi Zullof-Shani, Ph.D., will present on "5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator" on July 29th, highlighting MEAI's potential in addiction treatment. Additionally, researchers from The Hebrew University of Jerusalem will present findings on MEAI's effects on diet-induced obesity on July 30th.

Dr. Zullof-Shani will discuss MEAI's promising role in reducing alcohol consumption and controlling binge behaviors. Prof. Joseph Tam and Dr. Saja Baraghithy will showcase MEAI's potential in managing obesity, demonstrating its ability to reduce fat mass and improve metabolic health in mice. Clearmind, listed on Nasdaq and Frankfurt Stock Exchange, focuses on developing novel psychedelic-derived therapeutics to address major health challenges.

Read More - https://www.techdogs.com/tech-news/globe-newswire/clearmind-medicine-to-present-groundbreaking-research-at-psychedelic-medicine-israel-2024-conference